IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 6.89
(-0.14%)
SEK 6.89
(-0.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 61.35 Million SEK | 87.5% |
| 2022 | 32.72 Million SEK | -55.15% |
| 2021 | 72.96 Million SEK | 228.86% |
| 2020 | 22.18 Million SEK | -15.44% |
| 2019 | 26.24 Million SEK | 110.59% |
| 2018 | 12.46 Million SEK | 56.32% |
| 2017 | 7.97 Million SEK | -13.57% |
| 2016 | 9.22 Million SEK | 1.74% |
| 2015 | 9.06 Million SEK | -49.23% |
| 2014 | 17.85 Million SEK | 254971.43% |
| 2013 | 7000.00 SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 59.92 Million SEK | -2.34% |
| 2024 Q2 | 144.92 Million SEK | 141.86% |
| 2024 Q3 | 122.26 Million SEK | -15.64% |
| 2023 Q3 | 38.93 Million SEK | -10.73% |
| 2023 Q2 | 43.61 Million SEK | -5.55% |
| 2023 Q4 | 61.35 Million SEK | 57.58% |
| 2023 Q1 | 46.17 Million SEK | 41.11% |
| 2023 FY | 61.35 Million SEK | 87.5% |
| 2022 Q1 | 64.53 Million SEK | -11.55% |
| 2022 Q3 | 44.77 Million SEK | -15.21% |
| 2022 FY | 32.72 Million SEK | -55.15% |
| 2022 Q4 | 32.72 Million SEK | -26.92% |
| 2022 Q2 | 52.8 Million SEK | -18.18% |
| 2021 Q3 | 75.79 Million SEK | 192.54% |
| 2021 FY | 72.96 Million SEK | 228.86% |
| 2021 Q1 | 24.45 Million SEK | 10.22% |
| 2021 Q4 | 72.96 Million SEK | -3.73% |
| 2021 Q2 | 25.9 Million SEK | 5.94% |
| 2020 Q2 | 24.33 Million SEK | 41.86% |
| 2020 FY | 22.18 Million SEK | -15.44% |
| 2020 Q4 | 22.18 Million SEK | 6.97% |
| 2020 Q3 | 20.74 Million SEK | -14.77% |
| 2020 Q1 | 17.15 Million SEK | -34.62% |
| 2019 FY | 26.24 Million SEK | 110.59% |
| 2019 Q2 | 24.77 Million SEK | 42.7% |
| 2019 Q4 | 26.24 Million SEK | 21.57% |
| 2019 Q3 | 21.58 Million SEK | -12.88% |
| 2019 Q1 | 17.36 Million SEK | 39.34% |
| 2018 Q2 | 16.95 Million SEK | 53.93% |
| 2018 FY | 12.46 Million SEK | 56.32% |
| 2018 Q3 | 10.7 Million SEK | -36.89% |
| 2018 Q1 | 11.01 Million SEK | 38.2% |
| 2018 Q4 | 12.46 Million SEK | 16.43% |
| 2017 FY | 7.97 Million SEK | -13.57% |
| 2017 Q1 | 8.69 Million SEK | -5.74% |
| 2017 Q2 | 5.05 Million SEK | -41.86% |
| 2017 Q3 | 16.68 Million SEK | 229.97% |
| 2017 Q4 | 7.97 Million SEK | -52.21% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 9.22 Million SEK | 1.74% |
| 2016 Q4 | 9.22 Million SEK | 0.0% |
| 2015 FY | 9.06 Million SEK | -49.23% |
| 2014 FY | 17.85 Million SEK | 254971.43% |
| 2013 FY | 7000.00 SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Active Biotech AB (publ) | 13.4 Million SEK | -357.888% |
| Biovica International AB (publ) | 34.76 Million SEK | -76.481% |
| Cantargia AB (publ) | 54.97 Million SEK | -11.619% |
| CombiGene AB (publ) | 4.15 Million SEK | -1376.348% |
| Cyxone AB (publ) | 4.69 Million SEK | -1207.137% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -745.138% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -345.534% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -360.362% |
| Fluicell AB (publ) | 8.91 Million SEK | -588.245% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -32.865% |
| Mendus AB (publ) | 51.22 Million SEK | -19.779% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -220.168% |
| I-Tech AB | 16.2 Million SEK | -278.63% |
| Intervacc AB (publ) | 21.68 Million SEK | -183.012% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -1089.55% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 50.51% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -2500.975% |
| OncoZenge AB (publ) | 1.69 Million SEK | -3511.36% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -77.317% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 87.275% |
| Lipum AB (publ) | 7.53 Million SEK | -713.969% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 42.439% |
| Ziccum AB (publ) | 6.38 Million SEK | -860.504% |
| BioArctic AB (publ) | 139.5 Million SEK | 56.017% |
| Genovis AB (publ.) | 98.04 Million SEK | 37.421% |
| Camurus AB (publ) | 414.81 Million SEK | 85.209% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -280.697% |
| Aptahem AB (publ) | 8.99 Million SEK | -581.909% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -50.168% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 14.604% |
| Kancera AB (publ) | 17.97 Million SEK | -241.289% |
| Saniona AB (publ) | 86.08 Million SEK | 28.723% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -425.857% |
| AcouSort AB (publ) | 10.37 Million SEK | -491.222% |
| Xintela AB (publ) | 14.01 Million SEK | -337.795% |
| Abliva AB (publ) | 16.78 Million SEK | -265.634% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -430.357% |
| Amniotics AB (publ) | 10.54 Million SEK | -481.748% |
| 2cureX AB (publ) | 2.93 Million SEK | -1990.528% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1286.286% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 96.081% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 94.826% |
| Biosergen AB | 5.08 Million SEK | -1106.627% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -129.733% |
| Corline Biomedical AB | 6.78 Million SEK | -803.771% |
| NextCell Pharma AB | 13.68 Million SEK | -348.219% |
| Nanologica AB (publ) | 79.32 Million SEK | 22.653% |
| LIDDS AB (publ) | 3.75 Million SEK | -1533.573% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 71.409% |
| BioInvent International AB (publ) | 90.45 Million SEK | 32.167% |
| SynAct Pharma AB | 51.83 Million SEK | -18.372% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -671.883% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -1081.091% |
| Alzinova AB (publ) | 9.33 Million SEK | -557.561% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -381.458% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 66.213% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -3320.123% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -231.767% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -1498.671% |
| Simris Alg AB (publ) | 148.93 Million SEK | 58.804% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 13.725% |